The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis

Australasian Journal of Dermatology

Volumn 53, Issue 1, 2012, Pages 57-60

  Young, Lauren ^a   Czarnecki, D ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

biological agent; cutaneous malignancy; phototherapy; psoriasis; squamous cell carcinoma; ustekinumab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB;

ADULT; AGED; ARTICLE; BUTTOCK; CANCER GROWTH; CASE REPORT; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; KERATOACANTHOMA; MALE; PSORIASIS VULGARIS; PUVA; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; DERMATOLOGIC AGENTS; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PSORIASIS; SKIN NEOPLASMS;

EID: 84856975715     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2011.00853.x     Document Type: Article

References (16)

1. Jaou M, Bastuji-Garin S, Bourdon-Lanoy E, et al,. Poor agreement between self-reported and dermatologists' diagnoses for five common dermatoses. Br. J. Dermatol. 2006; 155: 1006-12. (Pubitemid 44564512)
2. Finlay AY, Coles EC,. The effect of severe psoriasis on the quality of life of 369 patients. Br. J. Dermatol. 1995; 132: 236-44.
3. Reich K, Leonardi C, Griffiths CEM, et al,. Update on the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. Presentation at the World Congresss of Dermatology, Seoul, Korea. May 24-29, 2011.
4. Janssen Inc. Stelara product information. Available from URL: (Accessed 5 Sept 2011.)
5. Farhi D,. Ustekinumab for the treatment of psoriasis. Drugs Today 2010; 46: 259-64.
6. Uhlenhake EE, Feldman SR,. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opin. Biol. Ther. 2010; 10: 1105-12.
7. Moustou AE, Matekovits A, Dessinioti C, et al,. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J. Am. Acad. Dermatol. 2009; 61: 486-504.
8. Ly L, Czarnecki D,. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br. J. Dermatol. 2007; 157: 1040-85.
9. Smith KN, Skelton HG,. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumour necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J. Am. Acad. Dermatol. 2001; 45: 953-6. (Pubitemid 33096643)
10. Esser AC, Abril A, Fayne S, et al,. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J. Am. Acad. Dermatol. 2004; 50: 75-7.
11. Fryrear RS II, Wiggins AK, Sangueza O, et al,. Rapid onset of squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J. Am. Acad. Dermatol. 2004; 51: 1026. (Pubitemid 39593030)
12. Menter A, Feldman SR, Weinstein GD, et al,. A randomised comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 2007; 56: e1-15.
13. Tyring S, Gordon KB, Poulin Y, et al,. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol. 2007; 143: 719-26. (Pubitemid 46955730)
14. Williams GM,. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur. J. Cancer Prev. 2008; 17: 169-77. (Pubitemid 351301629)
15. Starcher B,. Role for tumor necrosis factor-alpha receptors in ultraviolet-induced skin tumours. Br. J. Dermatol. 2000; 142: 1140-7. (Pubitemid 30418300)
16. Naldi L,. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporine, and biologics: facts and controversies. Clin. Dermatol. 2010; 28: 88-92.